Josh Gottheimer's INSM trades
- The latest INSM trade was a sale on Jun 10, 2026, when INSM closed at $91.88. It closed at $105.11 on Nov 3, 2026 (+14%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Josh Gottheimer reported 3 INSM transactions in 3 filings with the House Clerk for 2025–2026: 1 purchase and 2 sales of Insmed Incorporated - Common Stock, with trade dates from Apr 9, 2025 to Jun 10, 2026. The median gap between trade date and filing date is 30 days, and every trade was reported within 45 days.
- 3
- 1 / 2
- $3K – $45K
- 2026-07-07
INSM transactions reported by Josh Gottheimer
| Type | Owner | ||||
|---|---|---|---|---|---|
Insmed Incorporated - Common Stock INSM | Sale | Joint | $1,001 - $15,000 | 2026-07-07 #20034938 | |
Insmed Incorporated - Common Stock INSM | Purchase | Joint | $1,001 - $15,000 | 2025-07-16 #20030621 | |
Insmed Incorporated - Common Stock INSM | Sale | Joint | $1,001 - $15,000 | 2025-05-14 #20030338 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 2
- 31–45 days
- 1
- Over 45 days
- 0
- Median / longest
- 30d / 35d
What Josh Gottheimer's INSM filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchOther members of Congress who reported INSM
More tickers reported by Josh Gottheimer
Josh Gottheimer and INSM: questions
Did Josh Gottheimer buy or sell INSM?
House Clerk filings for 2025 and 2026 show 1 purchase and 2 sales of Insmed Incorporated - Common Stock (INSM) reported by Josh Gottheimer, between 2025-04-09 and 2026-06-10. Reported owner: Joint.
How much INSM did Josh Gottheimer trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $3K – $45K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last INSM filing by Josh Gottheimer?
The most recent filing that includes a INSM trade was filed on 2026-07-07. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Insmed Incorporated - Common Stock. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Josh Gottheimer INSM disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included